DPP-4 Inhibitora like Saxagliptin and Alogliptin may increase the Risk of Heart Failure

A U.S. Food and Drug Administration (FDA) safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.

Heart failure can result in the heart not being able to pump enough blood to meet the body’s needs. As a result, a new warning is being added to the drug labels about this safety issue.

Read more, Clinician On Net: DPP-4 Inhibitora like Saxagliptin and Alogliptin may increase the Risk of Heart Failure

Advertisements
  1. Leave a comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: